PHARMAIN CORPORATION
First- and best-in-class subcutaneous peptide therapeutics for liver cirrhosis and cancer
- Sector
- Biotech
- Headquarters
- Bothell, WA
- Latest Form D
- $1.5M, May 2014
- Total capital
- $16.8M
- Federal grants
- $15.3M
- 12 awards · 2015–2025
- Rank in peer group#18 of 514
- Private capital raised
- $1.5M
- 1 Form D · last May 2014
- 150 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 11
- 19 pending · first 2015
- Rank in peer group#28 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Subcutaneous Drug Development for Portal Hypertension Ascites$2.6M
- Federal grantHealth and Human S · Phase II · Subcutaneous Drug Development for Portal Hypertension Ascites$2.1M
- Federal grantHealth and Human S · Phase II · Development of an immunomodulating peptide as a therapy for osteosarcoma in canine and human$995K
- Federal grantHealth and Human S · Phase II · Development of an immunomodulating peptide as a therapy for osteosarcoma in canine and human$995K
- Federal grantHealth and Human S · Phase II · CMC of Peptide Formulation for the Treatment of ARDS$968K
- Federal grantHealth and Human S · Phase II · Subcutaneous Drug Development for Portal Hypertension Ascites$982K
- Federal grantHealth and Human S · Phase II · CMC of Peptide Formulation for the Treatment of ARDS$1.0M
- Private capital raisedForm D · SEC · 1st filing$1.5M
Show 5 earlier federal awards
- Federal grantHealth and Human S · Phase II · Subcutaneous Drug Development for Portal Hypertension Ascites$2M
- Federal grantHealth and Human S · Phase II · Development of Chemistry, Manufacturing, and Control Standards for PGC and PGC-dANP$1.0M
- Federal grantHealth and Human S · Phase II · Development of Chemistry, Manufacturing, and Control Standards for PGC and PGC-dANP$2M
- Federal grantHealth and Human S · Phase I · Subcutaneous Drug Development for Portal Hypertension Ascites$280K
- Federal grantHealth and Human S · Phase I · Medical countermeasure after radiation exposure$300K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#18 · top 4%
- Granted patents#28 · top 5%
- Linked publications#57 · top 11%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Elijah BolotinExecutive Officer, DirectorNamed in SEC Form D filings
- James FoghtDirectorNamed in SEC Form D filings
- John PresuttiDirectorNamed in SEC Form D filings
- Lester SalansDirectorNamed in SEC Form D filings
- Tibor PappDirectorNamed in SEC Form D filings
What it has protected
USPTO · 11 granted of 30- GrantedNpra Agonists, Compositions, And Uses ThereofUSPTOUS 12,679,877
- GrantedAnionic-core Composition For Delivery Of Therapeutic Agents, And Methods Of Making And Using The SameUSPTOUS RE50,618
- GrantedV1A Receptor Partial Agonist and Method of UseUSPTOUS 12,410,211
Show all 30 patent records
- Npra Agonists, Compositions, And Uses ThereofJul 14, 2026 · US 12,679,877Granted
- Anionic-core Composition For Delivery Of Therapeutic Agents, And Methods Of Making And Using The SameOct 7, 2025 · US RE50,618Granted
- V1A Receptor Partial Agonist and Method of UseSep 9, 2025 · US 12,410,211Granted
- C-Type Natriuretic Peptides and Methods Thereof in Treating Acute Lung InjuryDec 28, 2023 · Application 18009590Pending
- C-Type Natriuretic Peptides and Methods Thereof in Treating CancerAug 3, 2023 · Application 18009596Pending
- Method Of Production Of Graft Co-polymer Excipient With A Superior Peptide And Protein Binding PropertyJan 5, 2021 · US 10,882,961Granted
- Anionic-core Composition For Delivery Of Therapeutic Agents, And Methods Of Making And Using The SameAug 13, 2020 · Application 16829843Pending
- Anionic-core Composition For Delivery Of Therapeutic Agents, And Methods Of Making And Using The SameApr 21, 2020 · US 10,624,966Granted
- Npra Agonists, Compositions, And Uses ThereofJan 16, 2020 · Application 16577947Pending
- Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the SameDec 17, 2019 · US 10,507,248Granted
- Method Of Production Of Graft Co-polymer Excipient With A Superior Peptide And Protein Binding PropertyJul 31, 2018 · US 10,035,885Granted
- Hydrophobic Core Carrier Compositions For Delivery Of Therapeutic Agents, Methods Of Making And Using The SameAug 22, 2017 · US 9,737,615Granted
- Composition For Long-acting Peptide AnalogsMay 23, 2017 · US 9,657,078Granted
- Soluble Hydrophobic Core Carrier Compositions For Delivery Of Therapeutic Agents, Methods Of Making And Using The SameFeb 7, 2017 · US 9,562,111Granted
- Composition For Long-acting Peptide AnalogsJul 28, 2015 · US 9,090,664Granted
- Compositions For Delivery Of Therapeutics And Other MaterialsApplication PCTUS2007088010Pending
- Cationic Lipid For Covalent Modification Of PeptidesApplication 63493290Pending
- V1A Receptor Partial Agonist And Method Of UseApplication PCTUS2021041998Pending
- C-type Natriuretic Peptides And Methods Thereof In Treating CancerApplication PCTUS2021037061Pending
- C-type Natriuretic Peptides And Methods Thereof In Treating Acute Lung InjuryApplication PCTUS2021037031Pending
- Npra Agonists, Compositions, And Uses ThereofApplication PCTUS2018023491Pending
- Npra Agonists, Compositions, And Uses ThereofApplication 62475147Pending
- Method Of Production Of Graft Co-polymer Excipient With A Superior Peptide And Protein Binding PropertyApplication PCTUS2015058885Pending
- Anionic-core Composition For Delivery Of Therapeutic Agents, And Methods Of Making And Using The SameApplication PCTUS2010048145Pending
- Polymeric Carrier Compositions For The Delivery Of Active Agents, Methods Of Making And Using The SameApplication PCTUS2010000809Pending
- Compositions For Treatment With Metallopeptidases, Methods Of Making And Using The SameApplication PCTUS2009036648Pending
- Soluble Hydrophobic Core Carrier Compositions For Delivery Of Therapeutic Agents, Methods Of Making And Using The SameApplication PCTUS2009030678Pending
- Cationic-core Carrier Compositions For Delivery Of Therapeutic Agents, Methods Of Making And Using The SameApplication PCTUS2008083687Pending
- Composition For Long-acting Peptide AnalogsApplication PCTUS2008072148Pending
- Cationic Lipid For Covalent Modification Of PeptidesApplication PCTUS2024022344Pending
Recent research by its founders
- Depth Cameras for Frailty Assessment: A Dataset for Automatic Balance Tests Evaluation20250 cites
- Subcutaneous therapy for portal hypertension: PHIN-214, a partial vasopressin receptor 1A agonist20241 cites
- Insights into the Genital Microbiota of Women Who Experienced Fetal Death in Utero202313 cites
Related companies, and why
- JANGOBIO, LLCSimilar federal contract value in Biotech · null in contracts
- GEMNEO BIOSCIENCE, INC.Similar federal contract value in Biotech · null in contracts
- TriAltus Bioscience, LLCSimilar federal contract value in Biotech · null in contracts
- Lipomedics Inc.Similar federal contract value in Biotech · null in contracts
- METANOIA BIO LLCSimilar federal contract value in Biotech · null in contracts
- LOXAGEN INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .